相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy
Naveen Pemmaraju et al.
BLOOD (2019)
Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants
Christian Pecquet et al.
BLOOD (2019)
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Marie Robin et al.
HAEMATOLOGICA (2019)
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
Roni Tamari et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto et al.
HAEMATOLOGICA (2018)
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
Jean-Christophe Ianotto et al.
HAEMATOLOGICA (2018)
The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis
Rafael Kramann et al.
BLOOD (2018)
Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy
Edit Porpaczy et al.
BLOOD (2018)
The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
Elena Crisa et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis
Moo-Kon Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
Hans Michael Kvasnicka et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Safety and efficacy of combination therapy of interferon-alpha 2 and ruxolitinib in polycythemia vera and myelofibrosis
Stine Ulrik Mikkelsen et al.
CANCER MEDICINE (2018)
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2018)
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
John Mascarenhas et al.
JAMA ONCOLOGY (2018)
Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2018)
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
Lucia Masarova et al.
BLOOD (2018)
Genomic Landscape and Clinical Features of Triple-Negative Myelofibrosis
Kristen Pettit et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Myelofibrosis Treatment Algorithm 2018
Ayalew Tefferi et al.
BLOOD CANCER JOURNAL (2018)
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN
Shannon Elf et al.
BLOOD (2018)
Targeting the CALR interactome in myeloproliferative neoplasms
Elodie Pronier et al.
JCI INSIGHT (2018)
A 2-Year, Longitudinal, Prospective Study of the Effects of Eltrombopag on Bone Marrow in Patients with Chronic Immune Thrombcytpenia
Russell K. Brynes et al.
ACTA HAEMATOLOGICA (2017)
Primary myelofibrosis and its targeted therapy
Lindsey Shantzer et al.
ANNALS OF HEMATOLOGY (2017)
Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013
Ja Min Byun et al.
ANNALS OF HEMATOLOGY (2017)
Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Elisa Rumi et al.
BLOOD (2017)
Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway
Christina Roaldsnes et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan
Katsuto Takenaka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis
Patrizio Mazza et al.
LEUKEMIA & LYMPHOMA (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Pharmacologic management of myelofibrosis
Michael Leung et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2017)
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pegylated interferon alpha-2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial
K. Gowina et al.
LEUKEMIA RESEARCH (2017)
Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease
Giovanni Barosi et al.
LEUKEMIA RESEARCH (2017)
Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis
Matthew Decker et al.
NATURE CELL BIOLOGY (2017)
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms
Nur Soyer et al.
TURKISH JOURNAL OF HEMATOLOGY (2017)
Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase
Nael Alakel et al.
ONCOTARGETS AND THERAPY (2017)
Immunotherapy based approaches in myelofibrosis
Lucia Masarova et al.
EXPERT REVIEW OF HEMATOLOGY (2017)
The role of the extracellular matrix in primary myelofibrosis
O. Leiva et al.
BLOOD CANCER JOURNAL (2017)
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
Claire N. Harrison et al.
LANCET HAEMATOLOGY (2017)
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa et al.
LANCET HAEMATOLOGY (2017)
The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval
Andrew T. Kuykendall et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Allogeneic Stem Cell Transplantation in Myelofibrosis
Tania Jain et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Characterization of Mortality in Myelofibrosis
Benjamin Garmezy et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden
Irene Bertozzi et al.
ANNALS OF HEMATOLOGY (2017)
Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis
Jinming Song et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2017)
Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target
Rebekka K. Schneider et al.
CELL STEM CELL (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
Xenia Cabagnols et al.
BLOOD (2016)
Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study
Hans Michael Kvasnicka et al.
HISTOPATHOLOGY (2016)
Autoimmune Myelofibrosis in Systemic Lupus Erythematosus Report of Two Cases and Review of the Literature
Prasad R. Koduri et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2016)
Autoimmune Myelofibrosis in Systemic Lupus Erythematosus Report of Two Cases and Review of the Literature
Prasad R. Koduri et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2016)
Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Myeloproliferative neoplasms: Morphology and clinical practice
Tiziano Barbui et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Primary Idiopathic Myelofibrosis: Clinico-Epidemiological Profile and Risk Stratification in Pakistani Patients
Sadia Sultan et al.
Asian Pacific Journal of Cancer Prevention (2016)
Mutant calreticulin: when a chaperone becomes intrusive
Mario Cazzola
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
A rare case of myelofibrosis secondary to juvenile idiopathic arthritis
Neelesh Jain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12
Samer A. Srour et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Myelofibrosis: an update on drug therapy in 2016
Prithviraj Bose et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Abdallah Abou Zahr et al.
HAEMATOLOGICA (2016)
Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
Srdan Verstovsek et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
A. Kaifie et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Secondary Bone Marrow Fibrosis in Children And Young Adults An Institutional Experience
Esther P. Soundar et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2016)
Myeloproliferative Neoplasms, Version 2.2017
Ruben Mesa et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review
Salem H. Alshemmari et al.
MEDICAL PRINCIPLES AND PRACTICE (2016)
Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency
M. Criscuolo et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations (vol 6, e415, 2016)
D. Barraco et al.
BLOOD CANCER JOURNAL (2016)
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies
Abdallah Abou Zahr et al.
HAEMATOLOGICA (2016)
Myelofibrosis: to transplant or not to transplant?
Rebecca Devlin et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Prefibrotic Versus Overtly Fibrotic Primary Myelofibrosis: Clinical, Cytogenetic, Molecular and Prognostic Comparisons
Mythri Mudireddy et al.
BLOOD (2016)
Treatment-Related Infections and Risk Factors in Patients with Myeloproliferative Neoplasms Treated with Ruxolitinib
Amber C. King et al.
BLOOD (2016)
Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study
Russell K. Brynes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel et al.
BLOOD (2015)
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Rami S. Komrokji et al.
BLOOD (2015)
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
Nicolaus Kroeger et al.
BLOOD (2015)
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
Michael Deininger et al.
BLOOD (2015)
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial
Adam J. Mead et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011
Melissa A. Deadmond et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
Catriona Jamieson et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
N. M. Kroeger et al.
LEUKEMIA (2015)
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Talha Badar et al.
LEUKEMIA RESEARCH (2015)
The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms
Mads Emil Bjorn et al.
MEDIATORS OF INFLAMMATION (2015)
Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications
Aziz Nazha et al.
ONCOLOGIST (2015)
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
T. Barbui et al.
BLOOD CANCER JOURNAL (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
Myelofibrosis patients in Belgium: disease characteristics
T. Devos et al.
ACTA CLINICA BELGICA (2015)
How common are myeloproliferative neoplasms? A systematic review and meta-analysis
Glen J. Titmarsh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter
Giovanni Barosi
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Prognostication in MF: From CBC to cytogenetics to molecular markers
Amy Zhou et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
Odile Moulard et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up
Waleed Ghanima et al.
HAEMATOLOGICA (2014)
Autoimmune myelofibrosis: an update on morphologic features in 29 cases and review of the literature
Maria E. Vergara-Lluri et al.
HUMAN PATHOLOGY (2014)
Pathology reporting of bone marrow biopsy in myelofibrosis; application of the Delphi consensus process to the development of a standardised diagnostic report
Jose M. Raya et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms
Umberto Gianelli et al.
MODERN PATHOLOGY (2014)
ExtramedulLary Pulmonary Hematopoiesis Causing Pulmonary Hypertension and Severe Tricuspid Regurgitation Detected by Technetium-99m Sulfur Colloid Bone Marrow Scan and Single-Photon Emission Computed Tomography/CT
Syed Zama Ali et al.
KOREAN JOURNAL OF RADIOLOGY (2014)
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
E. Tenedini et al.
LEUKEMIA (2014)
U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype
A. Tefferi et al.
LEUKEMIA (2014)
Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis
A. Tabarroki et al.
LEUKEMIA (2014)
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
P. Guglielmelli et al.
LEUKEMIA (2014)
Epidemiology of myeloproliferative neoplasms in the United States
Jyotsna Mehta et al.
LEUKEMIA & LYMPHOMA (2014)
Are we altering the natural history of primary myelofibrosis?
Michael R. Savona
LEUKEMIA RESEARCH (2014)
The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke's Encephalopathy
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2014)
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
Animesh Pardanani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
World Health Organization-defined classification of myeloproliferative neoplasms: Morphological reproducibility and clinical correlations-The Danish experience
Ann Brinch Madelung et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
Efficacy and safety of pegylated-interferon-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups
Jean-Christophe Ianotto et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Differential diagnosis of myelofibrosis based on WHO 2008 criteria: Acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis
E. Bae et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2013)
Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases
Xin He et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
Hans Carl Hasselbalch
LEUKEMIA RESEARCH (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Long-term outcome of pomalidomide therapy in myelofibrosis
Kebede H. Begna et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
Hans Carl Hasselbalch
BLOOD (2012)
mTOR Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked Leukemogenesis
Demetrios Kalaitzidis et al.
CELL STEM CELL (2012)
Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis
John Mascarenhas et al.
CLINICAL CANCER RESEARCH (2012)
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
Veronique Gelsi-Boyer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Myelofibrosis: molecular and cell biological aspects
Hans Kreipe et al.
FIBROGENESIS & TISSUE REPAIR (2012)
The JAK2 exon 12 mutations: A comprehensive review
Linda M. Scott
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
Elias Jabbour et al.
BLOOD (2011)
Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification
Juergen Thiele et al.
BLOOD (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A phase-2 trial of low-dose pomalidomide in myelofibrosis
K. H. Begna et al.
LEUKEMIA (2011)
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
D. Caramazza et al.
LEUKEMIA (2011)
The role of Smad signaling in hematopoiesis and translational hematology
U. Blank et al.
LEUKEMIA (2011)
Thrombosis in primary myelofibrosis: incidence and risk factors
Tiziano Barbui et al.
BLOOD (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Stephen T. Oh et al.
BLOOD (2010)
Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea*
Eva Löfvenberg et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Reversal of myelofibrosis by hydroxyurea
Eva Löfvenberg et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Splenic Rupture in a Plasma Cell Leukemia, Mobilized with G-CSF for Autologous Stem Cell Transplant
Consuelo Funes et al.
JOURNAL OF CLINICAL APHERESIS (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
How I treat symptomatic splenomegaly in patients with myelofibrosis
Ruben A. Mesa
BLOOD (2009)
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
Constantine S. Tam et al.
BLOOD (2009)
Conventional cytogenetics in myelofibrosis: literature review and discussion
Kebede Hussein et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
5-Azacitidine has limited therapeutic activity in myelofibrosis
R. A. Mesa et al.
LEUKEMIA (2009)
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao et al.
SCIENCE (2009)
A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
A. Quintas-Cardama et al.
LEUKEMIA (2008)
Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status
A. Cortelezzi et al.
LEUKEMIA (2008)
Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres
David J. Kuter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Ayalew Tefferi et al.
BLOOD (2006)
Palliative goals, patient selection, and perioperative platelet management - Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
Ruben A. Mesa et al.
CANCER (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Thalidomide therapy for myelofibrosis with myeloid metaplasia
DA Thomas et al.
CANCER (2006)
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
XH Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Pathogenesis of myelofibrosis with myeloid metaplasia
A Tefferi
JOURNAL OF CLINICAL ONCOLOGY (2005)
Importance of plasma matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinase (TIMP) in development of fibrosis in agnogenic myeloid metaplasia
JC Wang
LEUKEMIA & LYMPHOMA (2005)
Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia
LN Faoro et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial
M Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Spontaneous splenic rupture with fatal outcome following G-CSF administration for myelodysplastic syndrome
DP O'Malley et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia
TL Reeder et al.
BLOOD (2003)
Idiopathic myelofibrosis associated with ulcerative colitis
E Arellano-Rodrigo et al.
LEUKEMIA & LYMPHOMA (2002)
Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis
A Schmitt et al.
BLOOD (2000)
分享论文
